HIMS Blowout Q3 Leads To Substantial Fair Value Bump

Hims & Hers delivered yet another blowout result for Q3 - this one the most impressive yet. Revenue growth accelerated to 77%, on the back of both the GLP-1 weight loss drug launch, and the 44% subscriber growth it helped drive. Even ex-GLP sales, revenues soared 40%. The weight loss drug launch has also supercharged the Hers brand, giving the company yet another growth avenue. The stock is up over 150% since we added it a year ago, but now looks like as good a time as ever to add. The fair value gets a substantial bump from $21 to $28.

Watch List

RDDT 10.05%
NTNX 29.26%
CRWD 65.47%
SE 31.15%
SNOW 6.81%
APPF 5.42%
PINS -24.39%

Buy List

SEMR -38.32%
TSM -37.31%
GOOG -51.11%
NYAX -54.27%
MSFT -30.38%
ODD -28.54%
ASR -27.02%
FLYW -38.32%
HRMY -55.59%
YOU -37.07%
ABNB -31.92%
MELI -34.01%
ADBE -40.86%

Hold List

VTEX -16.96%
ZETA -22.06%
CELH 42.92%
TOST 14.20%
CPNG -16.30%
HIMS -11.29%
PAYC -20.54%
MNDY 13.50%
GLBE -21.76%
ZS 23.36%
V -4.06%
ADSK -2.00%
NOW -1.99%
FTNT -5.23%
TEAM -5.08%